Polypectomy in Patients Taking Dual Antiplatelet Agents

Effects of Antiplatelets Discontinuation in Patients Receiving Polypectomy: Randomized Controlled Trial

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02865824

Enrollment

180

Registered

2016-08-15

Start date

2016-01-31

Completion date

2019-03-31

Last updated

2016-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colonic Polyps

Keywords

Colonoscopy

Brief summary

Current guidelines recommend discontinuation of antiplatelets (i.e clopidogrel) for 7 days in patients taking DAT (dual antiplatelet therapy) before colonoscopy and polypectomy. The purpose of this study was to examine if a) discontinuation of these drugs reduces bleeding risks during polypectomy and if b) discontinuation of these drugs increases the occurence of thromboembolic events.

Detailed description

Patients taking dual antiplatelets (DAT) and who visited for colonoscopy were eligible for enrollment in this study. On enrollment, patients were randomized to two groups. One group continued DAT and the other group discontinued antiplatelets (i.e. clopidogrel, ticagrelor, prasugrel) for 7 days before colonoscopy. If polyps (≤1 cm) were observed during colonoscopy, they were removed by cold snare polypectomy. The primary aim was to compared the delayed bleeding rates of the two groups.

Interventions

DRUGContinue thienopyridine

Patients continue dual antiplatelet therapies before colonoscopy. The patients continue taking thienopyridine before colonoscopy

DRUGDiscontinue thienopyridine

Patients who are taking dual antiplatelet therapies stop thienopyridine one week before they undergo colonoscopy

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

* patients over the age of 20 years undergoing routine colonoscopy * patients who are taking DAT (dual antiplatelet therapy)

Exclusion criteria

* patients not abiding to the study protocol * history of inflammatory bowel disease * severe comorbidities * American Society of Anesthesiology class III or more * pregnancy

Design outcomes

Primary

Measure	Time frame
Delayed bleeding requiring hemostasis after polypectomy	2 weeks

Secondary

Measure	Time frame
immediate bleeding requiring hemostasis after polypectomy	1 day

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026